Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Part of paid clinical trials in Mountain Brook, Alabama.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT04936308
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Arthritis, Psoriatic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Guselkumab — DRUGParticipants will receive guselkumab as SC injection.
- Placebo — DRUGParticipants will receive matching placebo as SC injection.
Study Details
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Key Dates
- Start date
- Sep 28, 2021
- Status verified
- Jun 2026
- Primary completion
- Oct 28, 2024
- Completion
- Jul 16, 2026
Study Design
- Enrollment
- 453 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1: Guselkumab and PlaceboParticipants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
- Experimental: Group 2: GuselkumabParticipants will receive guselkumab SC.
- Experimental: Group 3: Placebo Followed by GuselkumabParticipants will receive placebo SC and will cross over to receive guselkumab SC.
Primary Outcome Measure
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 [ Time Frame: At Week 24 ]
Locations (50)
Related coverage on Hipa.ai
- Guselkumab Shows Improved Psoriatic Arthritis ACR20 Response vs. PlaceboGuselkumab · Dec 8, 2025 · ClinicalTrials.gov
- Guselkumab Phase 3 for Psoriatic Arthritis Shows Improved ACR20 ResponseGuselkumab · Oct 28, 2024 · ClinicalTrials.gov
Find similar trials in Mountain Brook, AL
By research site
Arthritis Associates· Mountain Brook, ALArizona Arthritis and Rheumatology Research PLLC 2· Avondale, AZArizona Arthritis and Rheumatology Research PLLC 3· Flagstaff, AZArizona Arthritis and Rheumatology Research PLLC· Mesa, AZArizona Arthritis and Rheumatology Research PLLC 1· Phoenix, AZArizona Arthritis and Rheumatology Associates· Sun City, AZ
Related Studies
- IMPACT - AndHealth Autoimmune Research RegistryRecruiting · AndHealth · Columbus, Ohio
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePHASE3 · Recruiting · MoonLake Immunotherapeutics AG · Avondale, Arizona
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsPHASE3 · Recruiting · Janssen Research & Development, LLC · Atlanta, Georgia
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPHASE3 · Recruiting · Janssen Research & Development, LLC · Glendale, Arizona